{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-014773","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.965275+00:00","generated_at":"2026-05-30T03:49:24.708841+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xilio Q3 net loss $14.0M; Phase 1C vilastobart + atezolizumab shows partial responses in cold tumors","bullets":["Cash $61.3M as of Sept 30, 2024; cash runway through Q2 2025.","Phase 1C: 2 unconfirmed PRs (MSS CRC with liver lesion resolution, ampullary carcinoma); no Grade 4/5 treatment-related AEs.","RP2D selected: vilastobart 100 mg Q6W + atezolizumab 1200 mg Q3W; Phase 2 enrolling MSS CRC.","Initial Phase 2 data for vilastobart combo in ~20 MSS CRC patients expected Q4 2024; ~40 total by Q1 2025.","License revenue $2.3M from Gilead agreement; net loss $14.0M vs $16.7M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-014773","json":"https://secwatch.observer/filing/0001558370-24-014773.json","markdown":"https://secwatch.observer/filing/0001558370-24-014773.md","text":"https://secwatch.observer/filing/0001558370-24-014773.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024014773/0001558370-24-014773-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024014773/xlo-20241107x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:49:24.708841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}